why choose us

First received: November 16, 2023

Clinical Trial: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Idiopathic Inflammatory Myopathy

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy

Brief Summary: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy

Read more